The Molecular Pharmacology Program at SKI serves as a conduit for advancing basic biological discoveries into the preclinical and clinical settings. Our research spans the full spectrum of pharmacological interests, from small molecule drug development, drug sensitivity and resistance, molecular biology of drug action, cell signaling, drug delivery, transcriptional regulation, stem cells, and neuropharmacology to nanoparticle design and applications, smart drugs, imaging agents, and antibody, cell, vaccine, and cytokine therapies. Discoveries in the laboratory are often tested in clinic at Memorial Hospital, where many of our faculty also hold appointments.
Our multidisciplinary collaborations across the MSK community as well as with nearby Rockefeller University and Weill Cornell Medicine place us in a unique position to accelerate the development of novel therapies for patients.
Alex Kentsis, MD, PhD
Cancer biologist and pediatric oncologist Alex Kentsis leads research in the functional proteomics and molecular pharmacology of refractory childhood cancers.
Michael G. Kharas, PhD
Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.
Richard N. Kolesnick, MD
Physician-scientist Richard Kolesnick studies the role of ceramide signaling in radiation-induced vascular dysfunction and tumor regression.
Steven M. Larson, MD
Nuclear medicine physician Steven Larson focuses on molecular imaging in animals and humans using high-resolution diagnostic instruments, such as positron emission tomography, and single photon emission tomography.
Neal Rosen, MD, PhD
Pharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
Jason S. Lewis, PhD
Radiochemist Jason Lewis develops molecular imaging agents for the imaging and therapy of cancer.
Vladimir Ponomarev, MD, PhD
Physician-scientist Vladimir Ponomarev focuses on developing reporter genetic systems for specific applications such as sequential in vivo imaging studies in cancer biology, cancer immunotherapy, and radiation sciences.
Charles M. Rudin, MD, PhD
Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
Collaborations & Resources
SKI offers a wide array of core facilities and other technologies, as well as significant opportunity for collaboration across MSK. Members of the Molecular Pharmacology Program derive particular benefit from close ties to the following:
Education & Training
The Molecular Pharmacology Program regularly hosts postdoctoral fellows and students from the following graduate programs: